DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Other Events
Item8.01. Other Events.
On April27, 2017, the Company issued a Letter to Stockholders
providing a business update. A copy of the Letter to Stockholders
is attached as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated into this Item8.01 by reference.
Item9.01 Financial Statements and Exhibits
The following exhibit is filed herewith:
(d) Exhibits
| Exhibit99.1 | Letter to Stockholders of the Company, dated April27, 2017. |
About DELCATH SYSTEMS, INC. (NASDAQ:DCTH)
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver. DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Recent Trading Information
DELCATH SYSTEMS, INC. (NASDAQ:DCTH) closed its last trading session 00.0000 at 0.0608 with 6,876,301 shares trading hands.
